MUMBAI, India, Feb. 6 -- Intellectual Property India has published a patent application (202511131350 A) filed by Dr. Neeraj Jain, Lucknow, Uttar Pradesh, on Dec. 24, 2025, for 'niosomal in-situ gel ocular system for sustained glaucoma therapy.'
Inventor(s) include Dr. Neeraj Jain.
The application for the patent was published on Feb. 6, under issue no. 06/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a novel niosomal in-situ gel based ocular drug delivery system for sustained treatment of glaucoma. The system comprises an antiglaucoma drug encapsulated within non-ionic surfactant vesicles, which are incorporated into a pHresponsive mucoadhesive in-situ gel. Upon ocular administration, the formulation undergoes rapid sol-to-gel transition, prolonging precorneal residence time and enabling controlled drug release. The combined effect of vesicular entrapment and in-situ gelation results in enhanced ocular bioavailability, prolonged intraocular pressure reduction, reduced dosing frequency, and improved patient compliance. The formulation is nonirritant, isotonic, stable, and suitable for chronic ocular use, offering a superior therapeutic alternative to conventional antiglaucoma eye drops."
Disclaimer: Curated by HT Syndication.
